• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib.

作者信息

Pop Oana, Pirvu Augustin, Toffart Anne-Claire, Moro-Sibilot Denis

机构信息

Department of Oncology, University Hospital Grenoble, Grenoble, France.

出版信息

J Thorac Oncol. 2012 Aug;7(8):e1-2. doi: 10.1097/JTO.0b013e318257fc1d.

DOI:10.1097/JTO.0b013e318257fc1d
PMID:22797152
Abstract
摘要

相似文献

1
Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib.一名EML4-ALK肺癌患者在停用治疗药物并对克唑替尼产生获得性耐药后病情复发。
J Thorac Oncol. 2012 Aug;7(8):e1-2. doi: 10.1097/JTO.0b013e318257fc1d.
2
Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.与克唑替尼治疗伴有EML4-ALK易位的非小细胞肺癌相关的视神经病变和失明。
J Clin Oncol. 2015 Feb 10;33(5):e25-6. doi: 10.1200/JCO.2013.49.1985. Epub 2014 Mar 10.
3
Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.一名EML4-ALK阳性非小细胞肺癌患者接受克唑替尼治疗后发生严重急性间质性肺病。
J Clin Oncol. 2013 Jan 1;31(1):e15-7. doi: 10.1200/JCO.2012.43.3730. Epub 2012 Nov 19.
4
Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.克唑替尼诱发的急性间质性肺病，发生在一名EML4-ALK阳性非小细胞肺癌合并慢性间质性肺炎的患者身上。
Acta Oncol. 2014 Jan;53(1):158-60. doi: 10.3109/0284186X.2013.802838. Epub 2013 Jun 11.
5
Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.克唑替尼在中国EML4-ALK阳性晚期非小细胞肺癌患者中的疗效与安全性
PLoS One. 2014 Dec 12;9(12):e114008. doi: 10.1371/journal.pone.0114008. eCollection 2014.
6
HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.HIP1-ALK，一种新型的 ALK 融合变异体，对克唑替尼有反应。
J Thorac Oncol. 2014 Mar;9(3):285-94. doi: 10.1097/JTO.0000000000000087.
7
A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.一例对克唑替尼耐药的肺腺癌病例，携带一种新型EML4-ALK变异体，EML4的第6外显子与ALK的第18外显子融合。
J Thorac Oncol. 2016 Oct;11(10):e126-8. doi: 10.1016/j.jtho.2016.07.008.
8
Successful crizotinib retreatment after crizotinib-induced interstitial lung disease.克唑替尼诱发间质性肺病后成功再次使用克唑替尼治疗。
J Thorac Oncol. 2013 Aug;8(8):e73-4. doi: 10.1097/JTO.0b013e318293dfc1.
9
Analysis of ERBB ligand-induced resistance mechanism to crizotinib by primary culture of lung adenocarcinoma with EML4-ALK fusion gene.分析 EML4-ALK 融合基因肺腺癌原代培养物中 ERBB 配体诱导对克唑替尼耐药的机制。
J Thorac Oncol. 2015 Mar;10(3):527-30. doi: 10.1097/JTO.0000000000000381.
10
Crizotinib in the management of advanced-stage non-small-cell lung cancer.克唑替尼用于晚期非小细胞肺癌的治疗
Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314.

引用本文的文献

1
Prolonged Disease Control Despite ALK Inhibitor Discontinuation in Advanced ALK-Positive NSCLC.晚期ALK阳性非小细胞肺癌患者停用ALK抑制剂后疾病仍得到长期控制
Eur J Case Rep Intern Med. 2024 Apr 24;11(6):004527. doi: 10.12890/2024_004527. eCollection 2024.
2
An Observatory for the Oncogene: A Guide for Targeted Therapies.癌基因观察站：靶向治疗指南
Cancers (Basel). 2023 Sep 21;15(18):4672. doi: 10.3390/cancers15184672.
3
An mTOR feedback loop mediates the 'flare' ('rebound') response to MET tyrosine kinase inhibition.
mTOR 反馈回路介导 MET 酪氨酸激酶抑制的“爆发”（“反弹”）反应。
Sci Rep. 2023 Jan 25;13(1):1378. doi: 10.1038/s41598-023-28648-3.
4
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory -Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501).阿来替尼联合贝伐单抗治疗阿来替尼难治性ALK阳性非鳞状非小细胞肺癌的II期试验（NLCTG1501）
Cancers (Basel). 2022 Dec 29;15(1):204. doi: 10.3390/cancers15010204.
5
Multiple Brain Metastases in a Patient with ROS1 Fusion-Positive Lung Adenocarcinoma as a Disease Flare due to Crizotinib Cessation Caused by Disseminated Aseptic Inflammation from Crizotinib-Associated Renal Cysts: A Case Report.一名ROS1融合阳性肺腺癌患者因克唑替尼相关肾囊肿播散性无菌性炎症导致克唑替尼停药，进而出现疾病复发，表现为多发脑转移：一例报告
Case Rep Oncol. 2022 Mar 30;15(1):338-344. doi: 10.1159/000523737. eCollection 2022 Jan-Apr.
6
Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey on current practice, knowledge and challenges.大分割放疗联合靶向治疗或免疫治疗：荷兰当前实践、知识与挑战的调查
Clin Transl Radiat Oncol. 2022 Jan 28;33:93-98. doi: 10.1016/j.ctro.2022.01.002. eCollection 2022 Mar.
7
Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.肺癌中的假性进展和超进展：文献综述
J Cancer Res Clin Oncol. 2020 Dec;146(12):3269-3279. doi: 10.1007/s00432-020-03360-1. Epub 2020 Aug 28.
8
Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors.基于转录组学指导的转移性ALK阳性肺癌患者在ALK抑制剂复发后的靶向治疗个性化处方
Front Oncol. 2019 Oct 15;9:1026. doi: 10.3389/fonc.2019.01026. eCollection 2019.
9
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study.以治疗持续时间作为替代终点评估克唑替尼序贯治疗晚期 ALK 阳性非小细胞肺癌患者的疗效：一项回顾性、真实世界研究。
Cancer Med. 2019 Oct;8(13):5823-5830. doi: 10.1002/cam4.2420. Epub 2019 Aug 13.
10
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.在常规临床实践中治疗的慢性淋巴细胞白血病患者停止伊布替尼治疗后疾病迅速进展。
Leuk Lymphoma. 2019 Nov;60(11):2712-2719. doi: 10.1080/10428194.2019.1602268. Epub 2019 Apr 24.